Life Spine has earned U.S. Food and Drug Administration (FDA) clearance to market its ARx SAI (sacral alar iliac) spinal fixation system. The company said ARx SAI is the next generation in posterior fixation tech.

The first clinical cases using the ARx spinal fixation system took place in January 2023.

The system can be used through the SAI trajectory at the S1 and/or S2 levels. It touts versatile implants as well as streamlined, ergonomic instrumentation so customized solutions tailed to specific pathology can be constructed without sacrificing ease-of-use.

ARx SAI’s screw shank is based on Life Spine’s SImpact self-harvesting screw design. The design is self-drilling and recruits autograft during insertion. A low-profile, cobalt chrome tulip head offers greater strength, and a universal T25 hexalobe drive assists with ease-of-use and simplicity, Life Spine boasted.

“ARx SAI advances our commitment to innovation, positioning us among the pioneering spine companies to offer an SAI screw within our Lumbar Spinal Fixation Systems portfolio. ARx SAI delivers customizable solutions tailored to each patient, ensuring ease of use and versatile trajectory options,” said Mariusz Knap, senior VP of sales and marketing.

Earlier this year, Life Spine settled litigation against Aegis Spine which permanently barred Aegis from selling its AccelFIX-XT line of devices in the U.S.